Kailera Therapeutics Launches Global Phase 3 Program for Ribupatide in Obesity

New updates have been reported about Kailera Therapeutics.

Kailera Therapeutics has initiated its KaiNETIC global Phase 3 clinical program for ribupatide (KAI-9531), positioning the asset as its lead driver in the increasingly competitive obesity therapeutics market. The program has begun randomizing participants across three large, double-blind, placebo-controlled Phase 3 trials that will test once-weekly subcutaneous doses of up to 10 mg over 76 weeks, targeting adults with obesity or overweight, including those with type 2 diabetes and those with BMI of 35 kg/m2 or higher. KaiNETIC-1 will enroll about 1,800 participants without diabetes and measure percentage weight change at Week 76, while KaiNETIC-2 will enroll approximately 1,700 participants with type 2 diabetes and assess both weight reduction and hemoglobin A1c change. KaiNETIC-3 will enroll around 1,200 adults with BMI ≥35 kg/m2, comparing ribupatide (8 mg and 10 mg) to both placebo and open-label semaglutide 2.4 mg, with co-primary endpoints focused on relative weight-loss performance at Week 76.

The Phase 3 launch builds on prior clinical data generated by Kailera’s development partner Hengrui Pharma in China, where ribupatide (HRS9531) has already been submitted for marketing authorization for long-term weight management and showed approximately 23.6% mean weight loss at 36 weeks versus 1.8% with placebo, with no evident plateau and a safety profile in line with other GLP-1-based drugs. For Kailera, this milestone advances a broader obesity-first pipeline built around GLP-1–based mechanisms, including a once-daily oral tablet formulation of ribupatide, the oral small-molecule GLP-1 agonist KAI-7535, and the weekly GLP-1/GIP/glucagon tri-agonist KAI-4729. Executives are framing the KaiNETIC program as a critical step toward establishing ribupatide as a potential category-leading therapy, particularly for high-BMI populations projected to grow significantly by 2030, and as the cornerstone of a diversified portfolio aimed at capturing share across both injectable and oral obesity treatment segments.